Published in Sci Rep on April 17, 2015
Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. PLoS One (2015) 0.89
Mesenchymal Stem Cells Induce Directional Migration of Invasive Breast Cancer Cells through TGF-β. Sci Rep (2015) 0.82
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer. Front Pharmacol (2015) 0.82
Adhesion protein networks reveal functions proximal and distal to cell-matrix contacts. Curr Opin Cell Biol (2016) 0.80
Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling. Oncotarget (2016) 0.76
Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. Front Microbiol (2015) 0.76
β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation. Oncotarget (2016) 0.76
Mena confers resistance to Paclitaxel in triple-negative breast cancer. Mol Cancer Ther (2016) 0.75
A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clin Cancer Res (2016) 0.75
β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer. Int J Mol Sci (2016) 0.75
Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer. Oncol Lett (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Robust single-particle tracking in live-cell time-lapse sequences. Nat Methods (2008) 9.43
FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol (2004) 9.31
Nascent focal adhesions are responsible for the generation of strong propulsive forces in migrating fibroblasts. J Cell Biol (2001) 6.32
Spatiotemporal feedback between actomyosin and focal-adhesion systems optimizes rapid cell migration. Cell (2006) 6.02
Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase. Nat Cell Biol (2005) 4.99
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
Ovarian cancer. Lancet (2009) 3.95
Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling. Science (2004) 3.93
High resolution traction force microscopy based on experimental and computational advances. Biophys J (2007) 3.89
Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem (2007) 3.87
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
IntOGen: integration and data mining of multidimensional oncogenomic data. Nat Methods (2010) 3.63
Microtubule targeting of substrate contacts promotes their relaxation and dissociation. J Cell Biol (1999) 3.53
The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer (2011) 3.42
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res (2003) 3.30
Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci (2010) 3.17
Mechanisms of Taxol resistance related to microtubules. Oncogene (2003) 3.16
Involvement of microtubules in the control of adhesion-dependent signal transduction. Curr Biol (1996) 3.10
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol (2007) 2.98
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest (1997) 2.96
Analysis of microtubule dynamic instability using a plus-end growth marker. Nat Methods (2010) 2.67
Cell adhesion strengthening: contributions of adhesive area, integrin binding, and focal adhesion assembly. Mol Biol Cell (2005) 2.51
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol (2004) 2.12
Quantification of microtubule nucleation, growth and dynamics in wound-edge cells. J Cell Sci (2005) 2.09
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A (2001) 2.00
Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem (1991) 1.92
Coomassie staining as loading control in Western blot analysis. J Proteome Res (2011) 1.88
Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov (2011) 1.88
Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr (1993) 1.88
Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol (2004) 1.83
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol (1999) 1.64
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res (2005) 1.63
Microtubules in cell migration. Annu Rev Cell Dev Biol (2013) 1.62
Focal adhesion kinase modulates cell adhesion strengthening via integrin activation. Mol Biol Cell (2009) 1.60
Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med (2014) 1.50
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One (2013) 1.43
Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci U S A (1981) 1.41
Paxillin-dependent stimulation of microtubule catastrophes at focal adhesion sites. J Cell Sci (2008) 1.34
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol (2004) 1.33
Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res (2009) 1.32
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res (1997) 1.31
CLASPs link focal-adhesion-associated microtubule capture to localized exocytosis and adhesion site turnover. Nat Cell Biol (2014) 1.30
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (2008) 1.29
Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene (2010) 1.26
An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol (2005) 1.14
Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol (2004) 1.14
Adhesion dynamics at a glance. J Cell Sci (2011) 1.13
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol (2001) 1.07
Model of integrin-mediated cell adhesion strengthening. J Biomech (2006) 1.06
Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol (1997) 1.03
Differential mechanical response of mesenchymal stem cells and fibroblasts to tumor-secreted soluble factors. PLoS One (2012) 1.02
Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol (2007) 0.94
Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther (2001) 0.94
SNAIL-induced epithelial-to-mesenchymal transition produces concerted biophysical changes from altered cytoskeletal gene expression. FASEB J (2014) 0.93
Microtubule depolymerization induces traction force increase through two distinct pathways. J Cell Sci (2011) 0.93
Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer. Cancer Sci (2008) 0.92
High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol (2004) 0.91
Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health (2010) 0.89
Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin Cancer Res (1996) 0.88
The malignancy of metastatic ovarian cancer cells is increased on soft matrices through a mechanosensitive Rho-ROCK pathway. J Cell Sci (2014) 0.87
A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim Biophys Acta (2008) 0.86
Biomechanical analysis predicts decreased human mesenchymal stem cell function before molecular differences. Exp Cell Res (2012) 0.82
Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol (2013) 0.81